Evidence map›Paper›PMID 41444330›Full record

ArticleScientific reports2025

Enhanced classification prostate cancer based on generative adversarial networks and integrated deep learning with vision transformer models.

Wessam M Salama, Moustafa H Aly

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wessam M SalamaDepartment of Computer Engineering, Faculty of Engineering, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex 21648, Alexandria, Egypt.
Moustafa H AlyDepartment of Electronics and Communications Engineering, College of Engineering and Technology, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt. mosaly@aast.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By eliminating the need to alter the source images, this paper introduces a secure technique for coverless image steganography that strengthens defense against steganalysis attacks. Our method makes use of a hybrid Generative Adversarial Network (GAN) with a Support Vector Machine (SVM), which is trained and validated on a Diffusion Weighted Imaging (DWI) dataset to retain visually indistinguishable steganographic representations while increasing security. A powerful feature extraction capability of several Deep Learning Models (DLMs), EfficientNet-B4, DenseNet121, and Residual Network-18 (ResNet-18), integrated with the Vision Transformer (ViT) is performed. With the highest Peak Signal-to-Noise Ratio (PSNR) of 45.87 dB and Structural Similarity Index (SSIM) of 0.98, the ViT-GAN-SVM model exceeds other suggested models in terms of steganographic quality. Additionally, the ViT-GAN-SVM system achieves 99.78% accuracy, 99.85% sensitivity, 98.99% precision, and 99.85% F1-Score in terms of diagnostic accuracy. The ViT-GAN-SVM model performs much better than other introduced models in all diagnostic performance metrics, with increases ranging from 5.55% to 6.36%. This shows that ViT-GAN-SVM is a superior choice for medical diagnostic tasks since it can correctly identify prostate cancer on the DWI prostate cancer dataset.

Indexed as

Deep LearningImage Processing, Computer-AssistedProstatic NeoplasmsAlgorithmsDiffusion Magnetic Resonance ImagingGenerative Adversarial NetworksHumansMaleNeural Networks, ComputerSupport Vector MachineCoverless steganographyDeep learningGenerative adversarial networkProstate cancerSupport vector machine

Identifiers

PMID41444330
PMCPMC12738650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.